Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Discovery Laboratories Inc

+ Add to Watchlist


0.744 EUR 0.009 1.22%

As of 05:10:59 ET on 05/25/2015.

Snapshot for Discovery Laboratories Inc (DYBN)

Open: 0.744 Day's Range: 0.744 - 0.744 Volume: 0
Previous Close: 0.735 52wk Range: 0.682 - 1.680 1-Yr Rtn: -42.55%

Stock Chart for DYBN

No chart data available.
  • DYBN:GR 0.744
  • 1M
  • 1Y
Interactive DYBN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for DYBN

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -0.4083
Est. EPS (USD) (12/2015) -0.4600
Est. PEG Ratio -
Market Cap (M EUR) 63.80
Shares Outstanding (M) 85.75
30 Day Average Volume 892
Price/Book (mrq) 17.5006
Price/Sale (ttm) 26.7019
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/05/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for DYBN

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for DYBN

Discovery Laboratories, Inc. is a biopharmaceutical company that develops its proprietary surfactant technology as Surfactant Replacement Therapies (SRT) for respiratory diseases. Through this technology, pulmonary surfactants have the potential to be developed into a series of respiratory therapies for patients in the neonatal care unit, critical care unit and other hospital settings.

John G CooperPresident/CEOJohn A TattorySenior VP/CFO
Steven G SimonsonSenior VP/Chief Dev OfcrMary B TempletonSenior VP/Secy/Gen Cnsl
More Company Profile & Key Executives for DYBN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil